182 related articles for article (PubMed ID: 25818192)
1. The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin.
Hossain MM; Mukheem A; Kamarul T
Life Sci; 2015 Aug; 135():55-67. PubMed ID: 25818192
[TBL] [Abstract][Full Text] [Related]
2. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin.
Kishida K; Funahashi T; Shimomura I
Endocr Metab Immune Disord Drug Targets; 2012 Jun; 12(2):118-31. PubMed ID: 22236026
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin as a routine clinical biomarker.
Kishida K; Funahashi T; Shimomura I
Best Pract Res Clin Endocrinol Metab; 2014 Jan; 28(1):119-30. PubMed ID: 24417951
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist.
Ninomiya H; Hirata A; Kozawa J; Nakata S; Kimura T; Kitamura T; Yasuda T; Otsuki M; Imagawa A; Kaneto H; Funahashi T; Shimomura I
Intern Med; 2016; 55(9):1143-7. PubMed ID: 27150869
[TBL] [Abstract][Full Text] [Related]
6. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
[TBL] [Abstract][Full Text] [Related]
7. Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population.
Ramya K; Ayyappa KA; Ghosh S; Mohan V; Radha V
Gene; 2013 Dec; 532(2):253-62. PubMed ID: 24055485
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.
Kadowaki T; Yamauchi T; Kubota N; Hara K; Ueki K; Tobe K
J Clin Invest; 2006 Jul; 116(7):1784-92. PubMed ID: 16823476
[TBL] [Abstract][Full Text] [Related]
9. Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
Benz V; Kintscher U; Foryst-Ludwig A
Handb Exp Pharmacol; 2012; (214):387-410. PubMed ID: 23027460
[TBL] [Abstract][Full Text] [Related]
10. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
[TBL] [Abstract][Full Text] [Related]
11. Regulation effects of TZQ-F on adipocyte differentiation and insulin action.
Nan Xia J; Qin Zhang D; Du J; Wen J
J Ethnopharmacol; 2013 Nov; 150(2):692-9. PubMed ID: 24095827
[TBL] [Abstract][Full Text] [Related]
12. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.
Yin WH; Jen HL; Chen JW; Lin SJ; Young MS
Diabetes Metab; 2006 Jun; 32(3):229-35. PubMed ID: 16799399
[TBL] [Abstract][Full Text] [Related]
14. Convergence of adipocyte hypertrophy, telomere shortening and hypoadiponectinemia in obese subjects and in patients with type 2 diabetes.
Monickaraj F; Gokulakrishnan K; Prabu P; Sathishkumar C; Anjana RM; Rajkumar JS; Mohan V; Balasubramanyam M
Clin Biochem; 2012 Nov; 45(16-17):1432-8. PubMed ID: 22827962
[TBL] [Abstract][Full Text] [Related]
15. Modulation of adiponectin as a potential therapeutic strategy.
Lim S; Quon MJ; Koh KK
Atherosclerosis; 2014 Apr; 233(2):721-728. PubMed ID: 24603219
[TBL] [Abstract][Full Text] [Related]
16. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
17. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
[TBL] [Abstract][Full Text] [Related]
19. Association of adiponectin promoter variants with traits and clusters of metabolic syndrome in Arabs: family-based study.
Zadjali F; Al-Yahyaee S; Hassan MO; Albarwani S; Bayoumi RA
Gene; 2013 Sep; 527(2):663-9. PubMed ID: 23845780
[TBL] [Abstract][Full Text] [Related]
20. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
